Drugs & Targets FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer June 05, 2026Vol.52 No.22
Drugs & Targets FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm June 05, 2026Vol.52 No.22
Drugs & Targets European Commission authorizes expanded label for Venclyxto to include additional combinations in previously untreated CLL June 05, 2026Vol.52 No.22
PodcastThe Directors The Directors: NCORP PIs discuss workforce shortages, expanding workload, and crushing burden of regulatory oversight May 29, 2026Vol.52 No.21By Paul Goldberg and Claire Marie Porter
When CAM is added to standard therapies, survival rates drop, observational study finds May 29, 2026Vol.52 No.21By Jacquelyn Cobb
Trials & Tribulations As rural cancer disparities persist, aligning policy with care delivery models can close the gap May 29, 2026Vol.52 No.21By Matthew L. Anderson
Cancer Policy Protect the integrity of USPSTF, patient and provider groups urge in letter to Kennedy May 29, 2026Vol.52 No.21By Claire Marie Porter
Cancer Policy FDA issues a warning to retailers selling illegal tobacco products that resemble everyday items May 29, 2026Vol.52 No.21
